COVID-19 Related Research

While the COVID-19 pandemic has presented the medical and scientific community with unrelenting and unparalleled challenges, the unique nature of the Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2), which causes COVID-19, provides for wide-ranging and potentially impactful areas of scientific exploration and understanding.

  • Type of trial: observational (registry) 
  • PI: Dr. Virginia Steen and rheumatology faculty and  fellows  at GT and WHC
  • Description:  Any COVID 19 patient  that  has a rheumatic /autoimmune disease. This study is trying to understand how  our patients do as far as their high risk medication and  underlying diseases.  
  • Contact: Virginia Steen (steenv@georgetown.edu (new window)) or  Peter  Ban, MD  (fellow) (Byung.H.Ban@gunet.georgetown.edu)   
  • Start Date: Now (including any prior patients – can  be  retrospective)  
  • For DOM Faculty, Staff and Trainees: Please send us the  name and medical record number for the Covid 19 patients with any autoimmune disease. We have IRB approval to enter  deidentified data into this important rheumatology registry.

  1. Type of trial: Observational
  2. PI: Dr. Jose Vargas
  3. Description:  National study in collaboration with the NIH to do whole genome sequencing, RNA sequencing and proteomic analysis on COVID19 positive patients.  Our hypothesis is that clinical heterogeneity in response to viral infection is at least in part driven by genomic factors, current nationwide target is 2500 patients although this may increase depending on funds availability.  The study consists of one blood draw with the tubes being mailed to NIH for processing.
  4. Contact: Jose Vargas (Jose.d.vargas@medstar.net) 
  5. Start Date: Currently Under IRB Review
  6. For DOM Faculty, Staff and Trainees: Once study is approved we would like to for DoM faculty/trainees to be aware of the study as our study coordinator will be contacting primary team to asses feasibility of consent  

  • PI: Dr. Princy Kumar and Dr. Joseph Timpone
  • Description: Primary objective is to assess the clinical efficacy of ANG-3777 relative to standard of care in reducing the severity and progression of pulmonary dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia.
  • Contact: Dr. Kumar (KUMARP@gunet.georgetown.edu) or Dr. Timpone (TimponeJ@gunet.georgetown.edu)

  • PI: Dr. Princy Kumar and Dr. Joseph Timpone
  • Description: Primary objective is to evaluate the safety and efficacy of vazegepant (BHV-3500) compared with placebo in subjects hospitalized with COVID-19 infection requiring supplemental oxygen
  • Contact: Dr. Kumar (KUMARP@gunet.georgetown.edu) or Dr. Timpone (TimponeJ@gunet.georgetown.edu)

  • PI: Dr. Princy Kumar, Dr. Joseph Timpone, and Dr. Deepa Lazarous
  • Description: This Phase II study will investigate the pharmacodynamics, pharmacokinetics, safety, and efficacy of tocilizumab (TCZ) at two different doses (8mg/kg and 4mg/kg) in combination with standard-of-care (SOC) treatment in hospitalized patients with moderate to severe COVID-19 pneumonia.
  • Contact: Dr. Kumar (KUMARP@gunet.georgetown.edu), Dr. Timpone (TimponeJ@gunet.georgetown.edu), or Dr. Lazarous (DL28@gunet.georgetown.edu)

  • PI: Dr. Princy Kumar, Dr. Joseph Timpone, and Dr. Tunay Kuru
  • Description: The purpose of this study is to evaluate the efficacy and safety of the Janus Kinase (JAK) 1/2 inhibitor ruxolitinib in the treatment of patients with COVID-19-induced cytokine storm who require mechanical ventilation.
  • Contact: Dr. Kumar (KUMARP@gunet.georgetown.edu), Dr. Timpone (TimponeJ@gunet.georgetown.edu), or Dr. Kuru (TK53@gunet.georgetown.edu)

  • PI: Dr. Princy Kumar and Dr. Seble Kassaye
  • Description: A Randomized Controlled Double Blinded Phase 2 Study Comparing the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among Adults Exposed to COVID-19
  • Contact: Dr. Kumar (KUMARP@gunet.georgetown.edu) or Dr. Kassaye (Seble.G.Kassaye@gunet.georgtown.edu)

  • PI: Dr. Anne O’Donnell
  • Status: Waiting to receive contract
  • Contact: Dr. O’Donnell (ODONNELA@gunet.georgetown.edu)

  • PI: Dr. Catherine Broome
  • Status: Enrolling
  • Contact: Dr. Broome (Catherine.M.Broome@gunet.georgetown.edu)

  • PI: Dr. Alex Montero and Dr. Craig Kessler
  • Status: 
  • Contact: Dr. Montero (Alex.R.Montero@gunet.georgetown.edu) or Dr. Kessler (KESSLERC@gunet.georgetown.edu)

  • PI: Dr. Anne O’Donnell
  • Status: Data entry complete
  • Contact: Dr. O’Donnell (ODONNELA@gunet.georgetown.edu)

  • PI: Dr. Nathan Cobb
  • Status: Data entry ongoing
  • Contact: Dr. Cobb (Nathan.K.Cobb@gunet.georgetown.edu)